Alpha-2-Macroglobulin Emerges as Equine Joint Therapy

A blood protein called alpha-2-macroglobulin shows promise as an anti-inflammatory treatment for joint disease in horses. According to a review in the American Journal of Veterinary Research, this naturally occurring substance can protect cartilage and is now the basis for a commercial orthobiologic product.

Alpha-2-macroglobulin, or α2M, is a large glycoprotein found in all mammals. Its structure allows it to act as a broad-spectrum trap for protease enzymes. These enzymes, which break down proteins, are involved in the inflammation and cartilage degradation seen in conditions like osteoarthritis. When a protease attacks α2M, it triggers a conformational change that traps the enzyme, neutralizing it.

The Therapeutic Mechanism

This bait-and-trap mechanism is believed to be central to the protein's anti-inflammatory and cartilage-protective effects. Laboratory studies have demonstrated this activity. Researchers note that α2M is found in higher quantities in osteoarthritic equine joints compared to healthy ones. It is still unclear if this increase is the body's attempt to fight the disease or merely a byproduct of it.

Orthobiologics are treatments prepared from a patient's own blood. For joint therapy, they are processed to concentrate specific beneficial components for injection directly into the joint. Current evidence supports using these blood-based products to deliver concentrated α2M to inflamed synovial tissue. There, it can inhibit the proteases that drive the cycle of inflammation and cartilage breakdown.

Clinical Applications and Advantages

Clinicians might consider α2M orthobiologics when an acellular, concentrated product is needed. Potential indications include synovitis, cartilage damage, radiographic osteoarthritis, and cases of acute or repetitive trauma. The review authors, citing a separate paper, suggest α2M could be a safer alternative to corticosteroids for horses with certain metabolic conditions like pituitary pars intermedia dysfunction or insulin dysregulation, where steroid use raises laminitis concerns.

All blood-based orthobiologics contain some α2M, but the amount varies based on the processing method. The currently available equine α2M orthobiologic in the United States is Alpha2EQ by Creative Science. Its processing differs from other common orthobiologics like platelet-rich plasma or autologous conditioned serum.

Like other orthobiologics, multiple joints can be treated in a single session. This avoids potential complications associated with injecting multiple joints with corticosteroids.

Research and Unknowns

Researchers face challenges in studying α2M due to its large, complex structure and a lack of species-specific testing tools. There is no simple, reliable assay to quantify its concentration in orthobiologic products. Work is ongoing to develop better analytical methods, such as using mass spectrometry for detailed proteomic analysis. This could reveal other important proteins in the injectable products and provide a clearer picture of their clinical mechanism.

Patient-specific factors are another important area of investigation. The final composition of an orthobiologic-including concentrations of cells, proteins, and cytokines-can affect patient outcomes. Studies are examining how systemic health, dehydration, exercise status, medications, and metabolic diseases might influence the makeup of α2M orthobiologics and other autologous therapies.

Evidence of Effectiveness

Evidence to date illustrates that α2M orthobiologics prepared from both human and equine blood have antiprotease and anti-inflammatory effects. In cell culture studies using inflamed equine synovial cells, treatment with the commercial equine α2M product downregulated proinflammatory genes linked to osteoarthritis progression. This suggests an anti-inflammatory action beyond the classic bait-and-trap mechanism. A recent exploratory study in horses with chronic degenerative joint disease found that a European α2M orthobiologic reduced inflammatory mediator concentrations in joints one month after treatment.

While research continues to characterize α2M as an emerging treatment, current evidence supports its use as an anti-inflammatory joint therapy. The authors conclude that in blood-based orthobiologics, α2M is likely a potent component within a mix of innate bioactive factors that work together to reduce joint inflammation, pain, and lameness. As clinicians report positive outcomes, much remains to be uncovered about how each product exerts its beneficial effects inside the joint.